Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
F Schettini, P Barbao, F Brasó-Maristany, P Galván, D Martínez, L Paré, S De Placido, A Prat, S Guedan
BACKGROUND: Two promising therapeutic strategies in oncology are chimeric antigen receptor-T cell (CAR-T) therapies and antibody-drug conjugates (ADCs). To be effective and safe, these immunotherapies require surface antigens to be sufficiently expressed in tumors and less or not expressed in normal tissues. To identify new targets for ADCs and CAR-T specifically targeting breast cancer (BC) molecular and pathology-based subtypes, we propose a novel in silico strategy based on multiple publicly available datasets and provide a comprehensive explanation of the workflow for a further implementation...
April 7, 2021: ESMO Open
#2
Ju-Yoon Yoon, Leanne de Kock, Colin J R Stewart, W Glenn McCluggage, William D Foulkes, Blaise A Clarke, Marjan Rouzbahman
BACKGROUND: The uterus is one of the most dynamic organs in the human body, and this dynamic homeostasis is supported by endometrial stem/progenitor cells (ES/PCs), which are heterogeneous in their phenotype and degree of differentiation. ES/PCs are generally localized in the endometrial stroma, the site of origin for adenosarcoma and endometrial stromal sarcoma (ESS). Subsets of ESSs and adenosarcomas harbor SUZ12 or DICER1 gene alterations, two genes with roles in embryonic stem cell biology...
March 31, 2021: Cancer Treatment and Research Communications
#3
Saana E-M Andersson, Ilkka K Ilonen, Otto H Pälli, Jarmo A Salo, Jari V Räsänen
BACKGROUND: Robotic assistance in lung lobectomy has been suggested to enhance the adoption of minimally invasive techniques among surgeons. However, little is known of learning curves in different minimally invasive techniques. We studied learning curves in robotic-assisted versus video- assisted lobectomies for lung cancer. METHODS: A single surgeon performed his first 75 video-assisted thoracic surgery (VATS) lobectomies from April 2007 to November 2012, and his 75 first robotic-assisted thoracic surgery (RATS) lobectomies between August 2011 and May 2018...
April 2, 2021: Cancer Treatment and Research Communications
#4
REVIEW
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis.
Fausto Petrelli, Patrizia Giannatempo, Carmen Maccagnano, Roberto Contieri, Rodolfo Hurle
INTRODUCTION: One of the Non-Muscle Invasive Bladder Cancer (NMIBC) treatment options recently recommended by International Guidelines is represented by Active Surveillance (AS),. Herein we carried out a systematic review and pooled-analysis of currently available evidences in order to provide recommendations for daily urological practice. MATERIAL AND METHODS: The PubMed, EMBASE, and Coch rane Library databases were searched with the terms "Non-Muscle Invasive" or "pTa/pT1" and "Bladder Cancer" or "Bladder Tumor"...
April 3, 2021: Cancer Treatment and Research Communications
#5
REVIEW
Hsiu-Chung Cheng, Tsung-Kun Chang, Wei-Chih Su, Hsiang-Lin Tsai, Jaw-Yuan Wang
Diabetes mellitus (DM) and hyperglycemia have been shown to have significant effects on the incidence, chemoresistance, and prognosis of colorectal cancer (CRC), as well as the outcomes of localized and metastatic CRC. Inflammation and endocrine effects may act as central mechanisms of DM and cancer and stimulate the insulin-like growth factor 1-phosphoinositide 3-kinase-Akt-mammalian target of rapamycin (IGF-1-PI3K-AKT-mTOR) pathway. Dysregulation of the AMP-activated protein kinase (AMPK) pathway leads to metabolic imbalance and indicates cancer risk...
April 7, 2021: Translational Oncology
#6
G Morgan, M Tagliamento, M Lambertini, B Devnani, B Westphalen, R Dienstmann, I Bozovic-Spasojevic, A Calles, C Criscitiello, A Curioni, A M Garcia, A Lamarca, S Pilotto, M Scheffler, M Strijbos, R Wong, E de Azambuja, S Peters
BACKGROUND: The COVID-19 pandemic has impacted all aspects of modern-day oncology, including how stakeholders communicate through social media. We surveyed oncology stakeholders in order to assess their attitudes pertaining to social media and how it has been affected during the pandemic. MATERIALS AND METHODS: A 40-item survey was distributed to stakeholders from 8 July to 22 July 2020 and was promoted through the European Society for Medical Oncology (ESMO) and the OncoAlert Network...
April 7, 2021: ESMO Open
#7
Miguel Ángel González-Moles, Pablo Ramos-García, Saman Warnakulasuriya
No abstract text is available yet for this article.
April 7, 2021: Oral Oncology
#8
Jonathan Dismukes, Jessica Fazendin, Ruth Obiarinze, Gianina C Hernández Márquez, Kimberly M Ramonell, Erin Buczek, Brenessa Lindeman, Herbert Chen
BACKGROUND: Central neck dissection (CND) remains a controversial intervention for papillary thyroid carcinoma (PTC) patients with clinically negative nodes (cN0) in the central compartment. Proponents state that CND in cN0 patients prevents locoregional recurrence, while opponents deem that the risks of complications outweigh any potential benefit. Thus, there remains conflicting results amongst studies assessing oncologic and surgical outcomes in cN0 PTC patients who undergo CND. To provide clarity to this controversy, we sought to evaluate the efficacy, safety, and oncologic impact of CND in cN0 PTC patients at our institution...
April 7, 2021: Journal of Surgical Research
#9
REVIEW
Daniel A Erlanson, Kevin R Webster
The protein KRAS has for decades been considered a holy grail of cancer drug discovery. For most of that time, it has also been considered undruggable. Since 2018, five compounds have entered the clinic targeting a single mutant form of KRAS, G12C. Here, we review each of these compounds along with additional approaches to targeting this and other mutants. Remaining challenges include expanding the identification of inhibitors to a broader range of known mutants and to conformations of the protein more likely to avoid development of resistance...
April 7, 2021: Current Opinion in Chemical Biology
#10
Emmanuelle Jacquet, Ghania Kerouani-Lafaye, Francoise Grude, Sergio Goncalves, Annie Lorence, Florence Turcry, Liora Brunel, Laetitia Belgodere, Adrien Monard, Gaëlle Guyader, Lotfi Boudali, Nicolas Albin
INTRODUCTION: The cancer incidence continues to rise worldwide. Medical innovation has a major impact on patient survival, but within drug development, it can take more than 10 years to obtain marketing authorisation (MA). The time required for access to therapeutic innovation remains critical, so France has developed a specific expanded access program named ATU, which allows the administration of drugs before the European Medicines Agency (EMA) approval. The purpose of this study is to put in perspective the average time to access antineoplastic drugs worldwide, taking into account ATU, US Food and Drug Administration (FDA) and EMA approvals...
April 7, 2021: European Journal of Cancer
#11
REVIEW
Oded Cohen, Ralph P Tufano, AngKoon Anuwong, Ashok R Shaha, Kerry D Olsen, Mark Zafereo, Alessandra Rinaldo, Antti A Mäkitie, Iain J Nixon, Jonathon O Russell, Alfio Ferlito, Avi Khafif
OBJECTIVES: To describe the evolution and recent series on transoral endoscopic vestibular approach thyroidectomy and parathyroidectomy (TOET/PVA). DATA SOURCES: PubMed, Google Scholar. REVIEW METHODS: Review of the available English literature. RESULTS: TOET/PVA may offer several advantages over other remote access thyroidectomy approaches and has been adopted by many centers worldwide with excellent success rates. Indications include benign disease and early thyroid cancer patients...
March 31, 2021: American Journal of Otolaryngology
#12
EDITORIAL
David M Hyman, Jean-Charles Soria, Josep Tabernero
No abstract text is available yet for this article.
April 7, 2021: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#13
Sarwat Naz, Andrew J Leiker, Rajani Choudhuri, Olivia Preston, Anastasia L Sowers, Sangeeta Gohain, Janet Gamson, Askale Mathias, Carter Van Waes, John A Cook, James B Mitchell
PURPOSE: Recent pre-clinical studies suggest combining the HSP90 inhibitor AT13387 (Onalespib) with radiation (IR) against colon cancer and HNSCC. These studies emphasized that AT13387 down-regulates HSP90 client proteins involved in oncogenic signaling and DNA repair mechanisms as major drivers of enhanced radiosensitivity. Given the large array of client proteins HSP90 directs, we hypothesized that other key proteins or signaling pathways may be inhibited by AT13387 and contribute to enhanced radiosensitivity...
April 7, 2021: International Journal of Radiation Oncology, Biology, Physics
#14
Stephan Radonic, Jürgen Besserer, Valeria Meier, Carla Rohrer Bley, Uwe Schneider
PURPOSE: Tumor control probability (TCP) models based on Poisson statistics characterize the distribution of surviving clonogens. Thus enabling the calculation of TCP for individuals. In order to mathematically describe clinically observed survival data of patient cohorts it is necessary to extend the Poisson TCP model. This is typically done by either incorporating variations of model parameters, or by using an empirical logistic model. The purpose of this work is the development of an analytical population TCP model by mechanistic extension of the Possion model...
April 7, 2021: International Journal of Radiation Oncology, Biology, Physics
#15
Nicola Rares Franco, Michela Carlotta Massi, Francesca Ieva, Andrea Manzoni, Anna Maria Paganoni, Paolo Zunino, Liv Veldeman, Piet Ost, Valérie Fonteyne, Christopher J Talbot, Tim Rattay, Adam Webb, Kerstie Johnson, Maarten Lambrecht, Karin Haustermans, Gert De Meerleer, Dirk de Ruysscher, Ben Vanneste, Evert Van Limbergen, Ananya Choudhury, Rebecca M Elliott, Elena Sperk, Marlon Veldwijk, Carsten Herskind, Barbara Avuzzi, Barbara Noris Chiorda, Riccardo Valdagni, David Azria, Marie-Pierre Farcy-Jacquet, Muriel Brengues, Barry S Rosenstein, Richard G Stock, Ana Vega, Miguel Elías Aguado-Barrera, Paloma Sosa-Fajardo, Alison M Dunning, Laura Fachal, Sarah L Kerns, Debbie Payne, Jenny Chang-Claude, Petra Seibold, Catharine Ml West, Tiziana Rancati
AIM: To identify the effect of single nucleotide polymorphism (SNP) interactions on the risk of toxicity following radiotherapy (RT) for prostate cancer (PCa) and propose a new method for polygenic risk score incorporating SNP-SNP interactions (PRSi). MATERIALS AND METHODS: Analysis included the REQUITE PCa cohort that received external beam RT and was followed for 2 years. Late toxicity endpoints were: rectal bleeding, urinary frequency, haematuria, nocturia, decreased urinary stream...
April 7, 2021: Radiotherapy and Oncology
#16
Valerie Larouche, Caroline Bellavance, Pauline Tibout, Sebastien Bergeron, David Simonyan, Julie Gagné
OBJECTIVES: Chronic metabolic disturbances related to cancer treatment are well reported among survivors of pediatric acute lymphoblastic leukemia (ALL). However, few studies have investigated the incidence of these complications during the phase of chemotherapy. We evaluated the incidence of acute metabolic complications occurring during therapy in our cohort of patients diagnosed with ALL. METHODS: A prospective study involving 50 ALL pediatric patients diagnosed and treated between 2012 and 2016 in our oncology unit...
April 12, 2021: Journal of Pediatric Endocrinology & Metabolism: JPEM
#17
L Gutierrez-Sainz, P Cruz, S Martinez-Recio, O Higuera, M I Esteban-Rodriguez, F Arias-Lotto, R A Gonzalez, J De Castro-Carpeño
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, with a poor prognosis. MPM needs to find prognostic factors of survival. We provided the management of patients with MPM and sought to determine whether pre-treatment levels of derived neutrophil-to-lymphocyte ratio (dNLR) as well as PD-L1 expression were reliable prognostic factors of survival. METHODS: We conducted a single-institution retrospective study, including all patients with MPM treated at La Paz University Hospital between December 2009 and March 2018...
April 10, 2021: Clinical & Translational Oncology
#18
Valentine Ruste, Marie Pierre Sunyach, Ronan Tanguy, Emmanuel Jouanneau, Camille Schiffler, Mélodie Carbonnaux, Guillaume Moriceau, Eve-Marie Neidhardt, Helen Boyle, Sophie Robin, Sylvie Négrier, Aude Fléchon
PURPOSE: Brain metastases (BM) usually represent a poor prognostic factor in solid tumors. About 10% of patients with renal cancer (RCC) will present BM. Local therapies such as stereotactic radiotherapy (SRT), whole brain radiotherapy (WBRT), and surgery are used to achieve brain control. We compared survival between patients with synchronous BM (SynBM group) and metachronous BM (MetaBM group). METHODS: It is a retrospective study of patients with clear cell renal cell carcinoma (ccRCC) and BM treated with TKI between 2005 and 2019 at the Centre Léon Bérard in Lyon...
April 10, 2021: Journal of Neuro-oncology
#19
Kristoffer B Kristensen, Ida Marie Nedergaard Thomsen, Tobias Berg, Annette R Kodahl, Anders Bonde Jensen
PURPOSE: Treatment for estrogen receptor positive (ER+), human epidermal receptor 2 negative (HER2-) metastatic breast cancer (MBC) has improved with the approval of CDK 4/6 inhibitors. Clinical trials with the CDK4/6 inhibitor ribociclib, suggest that 35% to 57.5% of the patients require a dose reduction during ribociclib treatment. Data on the possible consequences of dose reduction concerning efficacy is needed. METHODS: A retrospective cohort study on patients with ER+ HER2- MBC from three Danish oncology departments...
April 10, 2021: Breast Cancer Research and Treatment
#20
Beate Husain, Michael Constantin Kirchberger, Michael Erdmann, Sabine Schüpferling, Amir-Reza Abolhassani, Waltraud Fröhlich, Carola Berking, Lucie Heinzerling
PURPOSE: Immune checkpoint inhibitors (ICI) are highly effective in several cancer entities, but also invoke a variety of immune-related adverse events (irAE). These are mostly reversible, but can be life-threatening or even fatal. Currently, the pathogenesis is not fully understood, but crucial for effective treatment. Prediction and early detection of irAE could be facilitated and treatment optimized if relevant biomarkers and effector mechanisms were better characterized. METHODS: This study included a total of 45 irAE in patients with metastatic melanoma who were treated with ICI...
April 10, 2021: Journal of Cancer Research and Clinical Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
